FR2973249B1 - Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c - Google Patents

Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c

Info

Publication number
FR2973249B1
FR2973249B1 FR1152536A FR1152536A FR2973249B1 FR 2973249 B1 FR2973249 B1 FR 2973249B1 FR 1152536 A FR1152536 A FR 1152536A FR 1152536 A FR1152536 A FR 1152536A FR 2973249 B1 FR2973249 B1 FR 2973249B1
Authority
FR
France
Prior art keywords
hepatitis
antiviral agent
virus infections
epigallocatechin gallate
epigallocatechin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1152536A
Other languages
English (en)
Other versions
FR2973249A1 (fr
Inventor
Karin Seron
Jean Dubuisson
Yves Rouille
Czeslaw Wychowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1152536A priority Critical patent/FR2973249B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/EP2012/055533 priority patent/WO2012130893A1/fr
Priority to CN201280026189.0A priority patent/CN103826626A/zh
Priority to JP2014501600A priority patent/JP2014510740A/ja
Priority to EP12711160.7A priority patent/EP2691091A1/fr
Priority to BR112013024904A priority patent/BR112013024904A2/pt
Priority to US14/008,031 priority patent/US20140088184A1/en
Publication of FR2973249A1 publication Critical patent/FR2973249A1/fr
Application granted granted Critical
Publication of FR2973249B1 publication Critical patent/FR2973249B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1152536A 2011-03-28 2011-03-28 Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c Expired - Fee Related FR2973249B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1152536A FR2973249B1 (fr) 2011-03-28 2011-03-28 Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c
CN201280026189.0A CN103826626A (zh) 2011-03-28 2012-03-28 表没食子儿茶素没食子酸酯作为抗丙型肝炎病毒感染的抗病毒试剂的应用
JP2014501600A JP2014510740A (ja) 2011-03-28 2012-03-28 Ｃ型肝炎ウイルスによる感染に対する抗ウイルス剤としてのエピガロカテキンガレートの使用
EP12711160.7A EP2691091A1 (fr) 2011-03-28 2012-03-28 Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hépatite c
PCT/EP2012/055533 WO2012130893A1 (fr) 2011-03-28 2012-03-28 Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hépatite c
BR112013024904A BR112013024904A2 (pt) 2011-03-28 2012-03-28 composto e método ex vivo de redução da infecciosidade ou de inativação de um vírus da hepatite c
US14/008,031 US20140088184A1 (en) 2011-03-28 2012-03-28 Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1152536A FR2973249B1 (fr) 2011-03-28 2011-03-28 Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c

Publications (2)

Publication Number Publication Date
FR2973249A1 FR2973249A1 (fr) 2012-10-05
FR2973249B1 true FR2973249B1 (fr) 2014-02-07

Family

ID=45895499

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1152536A Expired - Fee Related FR2973249B1 (fr) 2011-03-28 2011-03-28 Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c

Country Status (7)

Country Link
US (1) US20140088184A1 (fr)
EP (1) EP2691091A1 (fr)
JP (1) JP2014510740A (fr)
CN (1) CN103826626A (fr)
BR (1) BR112013024904A2 (fr)
FR (1) FR2973249B1 (fr)
WO (1) WO2012130893A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980259B (zh) * 2013-02-07 2017-08-01 上海唐润医药科技有限公司 黄酮类或异黄酮类化合物及其用途
CN104610272B (zh) * 2013-11-05 2017-03-29 上海唐润医药科技有限公司 环状黄酮或异黄酮类化合物及其用途
KR101843564B1 (ko) * 2015-06-11 2018-05-15 연세대학교 산학협력단 녹차 추출물에 의해 불활화된 바이러스를 포함하는 백신 및 그의 제조방법
CN112312886A (zh) * 2018-06-19 2021-02-02 株式会社资生堂 毛发染发剂
FR3121038B1 (fr) * 2021-03-27 2024-06-14 Nitcheu Guy Faustin Monkam Composition pharmaceutique destinée à inhiber l’infectiosité des virus à bicouche lipidique, à traiter les maladies associées et leurs complications.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09227374A (ja) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd ストレスタンパク質産生抑制組成物
WO1997041137A1 (fr) * 1996-04-17 1997-11-06 Unifob Utilisation d'anthocyanidine et de derives d'anthocyanidine
DE60031921T2 (de) 1999-08-16 2007-09-20 Dsm Ip Assets B.V. Verfahren zu Herstellung von Epigallocatechin Gallate
JP2001348382A (ja) * 1999-10-07 2001-12-18 Ito En Ltd ダイオキシン毒性発現阻止剤
US6383392B1 (en) 1999-11-16 2002-05-07 Roche Vitamins, Inc. Process for concentrating epigallocatechin gallate
AUPQ504300A0 (en) 2000-01-11 2000-02-03 Biorex Health Limited Extraction of flavonoids
US20030180719A1 (en) * 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
JP2006094825A (ja) * 2004-09-30 2006-04-13 Saga Univ カテキンタイプのカテキン類高含有茶葉
WO2008111589A1 (fr) 2007-03-12 2008-09-18 National University Corporation Kagawa University Procédé de production d'anthocyanine purifiée
WO2008115804A1 (fr) 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Nouveaux inhibiteurs ido et leurs procédés d'utilisation
CN101744830B (zh) * 2008-06-17 2012-09-05 上海医药工业研究院 黄酮类化合物或含其的植物提取物的应用
KR101023158B1 (ko) * 2008-07-23 2011-03-18 경상대학교산학협력단 머루로부터 분리된 안토시아닌을 함유하는 간암 예방 및치료용 조성물
JP4892690B2 (ja) * 2008-09-03 2012-03-07 財団法人宮崎県産業支援財団 Ｃ型肝炎ウイルス産生抑制剤
EP2179722A1 (fr) * 2008-10-24 2010-04-28 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Formation topique pour la prévention de la transmission sexuelle d'une infection virale
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
PL2416794T3 (pl) * 2009-04-10 2014-09-30 El Khatib Nadia Kompozycje na bazie roślin do zapobiegania lub leczenia wirusowych chorób przenoszonych przez krew spowodowanych ludzkim wirusem niedoboru odporności (HIV) lub zapalenia wątroby typu C
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection

Also Published As

Publication number Publication date
WO2012130893A1 (fr) 2012-10-04
JP2014510740A (ja) 2014-05-01
CN103826626A (zh) 2014-05-28
FR2973249A1 (fr) 2012-10-05
EP2691091A1 (fr) 2014-02-05
BR112013024904A2 (pt) 2019-09-24
US20140088184A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
HK1256490A1 (zh) 用於治療病毒感染的嘧啶衍生物
FR17C1040I2 (fr) Derive antiviraux de 2,5-dibenzimidazol-5-yl-1-phenyl-pyrrolidine
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
SMT201600142B (it) Indoli come agenti antivirali contro il virus respiratorio sinciziale
EP2726459A4 (fr) Dérivés de sulfamoylbenzamide en tant qu'agents antiviraux contre une infection par vhb
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
EA201492205A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
MD20140135A2 (ro) Inhibitori macrociclici ai viruşilor din familia Flaviviridae
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
EP2558466A4 (fr) Phosphonates présentant une toxicité réduite pour le traitement d'infections virales
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
FR2973249B1 (fr) Utilisation de l'epigallocatechine gallate comme agent antiviral contre les infections par le virus de l'hepatite c

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20171130